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Abstract
Purpose In the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole 
significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal 
growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC) [hazard ratio (HR) 0.58; P < 0.001]. Herein, we 
report results overall and by subgroups with extended follow-up.
Methods In this double-blind, phase 3 study, post-menopausal women with ER+/HER2− ABC who had not received prior 
systemic therapy for their advanced disease were randomized 2:1 to palbociclib-letrozole or placebo-letrozole. Endpoints 
include investigator-assessed PFS (primary), safety, and patient-reported outcomes (PROs).
Results After a median follow-up of approximately 38 months, median PFS was 27.6 months for palbociclib–letrozole 
(n = 444) and 14.5 months for placebo-letrozole (n = 222) (HR 0.563; 1-sided P < 0.0001). All subgroups benefited from 
palbociclib treatment. The improvement of PFS with palbociclib-letrozole was maintained in the next 2 subsequent lines of 
therapy and delayed the use of chemotherapy (40.4 vs. 29.9 months for palbociclib–letrozole vs. placebo-letrozole). Safety 
data were consistent with the known profile. Patients’ quality of life was maintained.
Conclusions With approximately 15 months of additional follow-up, palbociclib plus letrozole continued to demonstrate 
improved PFS compared with placebo plus letrozole in the overall population and across all patient subgroups, while the 
safety profile remained favorable and quality of life was maintained. These data confirm that palbociclib-letrozole should be 
considered the standard of care for first-line therapy in patients with ER+/HER2− ABC, including those with low disease 
burden or long disease-free interval. Sponsored by Pfizer; ClinicalTrials.gov: NCT01740427.
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ITT  Intent-to-treat
LET  Letrozole
MedDRA  Medical Dictionary for Regulatory Activities
NE  Not estimable
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PBO  Placebo
PFS  Progression-free survival
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STEPP  Subpopulation treatment effect pattern plot
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Introduction
Endocrine therapy has been the primary first-line treatment for 
hormone receptor-positive (HR+)/human epidermal growth 
factor receptor 2-negative (HER2−) advanced breast cancer 
(ABC) [1–3]. Recently, guidelines have expanded to include 
the addition of a cyclin-dependent kinase 4/6 (CDK4/6) inhibi-
tor in combination with endocrine therapy for the treatment of 
pre-menopausal/post-menopausal women with HR+/HER2‒ 
ABC [1–3].
In the PALOMA-2 study, palbociclib-letrozole sig-
nificantly prolonged progression-free survival (PFS) ver-
sus placebo-letrozole [median PFS, 24.8 vs. 14.5 months, 
respectively; hazard ratio [HR], 0.576 (95% CI 0.463–0.718); 
P < 0.0001] [4, 5]. The primary analysis was conducted after 
a median 23 months of follow-up (data cut-off: February 26, 
2016), with the investigators and patients remaining blinded 
to treatment assignments. Because patients with HR+/
HER2− ABC receiving first-line therapy have diverse clini-
cal and molecular presentations (e.g., de novo versus recurrent 
disease, visceral versus bone-only), response to endocrine-
based therapy could be prolonged in a particular subgroup. 
Therefore, it is important to analyze the long-term efficacy 
of treatment with extended follow-up in different patient 
subgroups.
Currently, PALOMA-2 has the longest follow-up of any 
phase 3 study investigating CDK4/6 inhibitors for HR+/
HER2− disease. In this report, we present updated efficacy, 
safety, and patient-reported outcome (PRO) results for the 
overall PALOMA-2 study population and across subgroups 
after extended patient follow-up. This study is ongoing to col-
lect overall survival data.
Methods
Study design, treatment, and patient eligibility 
criteria
Eligibility criteria and study design details were reported 
previously [4]. PALOMA-2 was a double-blind, inter-
national, phase 3 study in which women with estrogen 
receptor-positive (ER+)/HER2− advanced breast cancer 
were randomized 2:1 to receive letrozole 2.5 mg/day con-
tinuously and either palbociclib (125 mg/day, 3 weeks on 
followed by 1 week off of a 4-week cycle) or matching 
placebo. The study protocol was reviewed and approved by 
institutional review boards/independent ethics committees 
at each site (Table S1) and was conducted in accordance 
with Good Clinical Practice principles and the Declara-
tion of Helsinki. Informed consent was obtained from all 
individual participants included in the study.
Endpoints and assessments
The study’s primary endpoint was investigator-assessed 
PFS, defined as the time from date of randomization to 
the date of first documented objective disease progres-
sion (per Response Evaluation Criteria in Solid Tumors, 
v1.1) or death due to any cause, whichever occurred first. 
A blinded, independent central review of all patients was 
performed in a third party facility. Secondary endpoints 
included patient-reported outcomes (PROs), pharma-
cokinetics, and safety assessments. Subgroup analyses 
by baseline characteristics were pre-specified. Patient-
reported breast cancer-specific health-related quality of 
life (HRQOL) was assessed using the Functional Assess-
ment of Cancer Therapy-Breast (FACT-B) completed on-
site at baseline (day 1 of cycle 1), day 1 of cycles 2 and 3, 
and day 1 of every other cycle from cycle 5 until progres-
sion or end of treatment [6–8]. Adverse events (AEs) were 
recorded during study treatment until 28 days after the 
last treatment dose. AEs were graded for severity accord-
ing to the National Cancer Institute Common Terminol-
ogy Criteria for Adverse Events version 4.0 and classified 
according to Medical Dictionary for Regulatory Activities 
(MedDRA, v20.0).
In addition to these endpoints, time to initiation of sub-
sequent anticancer therapies (including chemotherapy) was 
assessed in the overall study population as an exploratory 
analysis to investigate whether palbociclib–letrozole treat-
ment affected subsequent therapies. The time to initiation of 
subsequent therapy was defined as the time from randomi-
zation to the start date of subsequent systemic anticancer 
therapy or death from any cause, whichever occurred first.
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Statistical analyses
Progression-free survival was evaluated in the overall 
intent-to-treat (ITT) population and in preplanned sub-
groups defined by their baseline characteristics. Time to 
subsequent therapies was evaluated in the ITT population. 
The Kaplan–Meier method was used to estimate median 
PFS and time to subsequent systemic anticancer therapies 
(including chemotherapy) by treatment arm. Hazard ratios 
for PFS and time to first and second subsequent systemic 
anticancer therapies were estimated from the Cox propor-
tional hazards model with a 95% CI; 1-sided P values were 
from the log-rank test. No adjustments were made for mul-
tiple testing. Repeated-measures mixed effects models were 
used to assess the effect on changes from baseline in patient-
reported quality of life using intercept term, treatment, time, 
treatment-by-time, and baseline as covariates. A subpopula-
tion treatment effect pattern plot (STEPP) [9] analysis was 
performed to explore whether PFS benefit was affected by 
a patient’s treatment-free interval (TFI) at baseline, where 
TFI (equivalent to the protocol-defined disease-free interval 
[DFI]) was defined as the time from the end of (neo)adjuvant 
therapy to disease progression. AE data were analyzed for 
patients who received ≥ 1 dose of study drug.
Results
Patients
From February 2013 through July 2014, 666 post-menopau-
sal women were enrolled and randomly assigned to receive 
palbociclib-letrozole (n = 444) or placebo-letrozole (n = 222) 
(Fig. S1). Demographics and baseline disease characteristics 
were well balanced between treatment arms and similar to 
that previously reported [4] (Table S2). Exposure to palbo-
ciclib or placebo is summarized in Table S3.
Efficacy
At the new data cut-off date (May 31, 2017), median (inter-
quartile range) follow-up was 37.6 (37.2–38.0) months in 
the palbociclib-letrozole arm and 37.3 (36.3–37.9) months 
in the placebo-letrozole arm. Investigator-assessed PFS 
was significantly longer with palbociclib-letrozole versus 
placebo-letrozole in the ITT population, with a median 
of 27.6 months (95% CI 22.4‒30.3) versus 14.5 months 
(12.3‒17.1), respectively [HR, 0.563 (95% CI 0.461–0.687); 
P < 0.0001] (Fig. 1a). This improvement in PFS with palbo-
ciclib was supported by the results of the updated blinded 
independent central review: median PFS 35.7 months (95% 
CI 27.7–38.9) versus 19.5 months (16.6–26.6), respectively 
[HR, 0.611 (95% CI 0.485–0.769); P < 0.0001].
Median PFS was also longer with palbociclib-letro-
zole across all subgroups examined (Fig. 1b). Notably, 
a substantial benefit in PFS with palbociclib-letrozole 
was observed for patients with a low disease burden such 
as non-measurable disease (4% visceral), bone-only dis-
ease, or single disease site. For patients with non-visceral 
disease who did not receive prior endocrine therapy, the 
median PFS exceeded 3 years with palbociclib-letrozole 
(Figs. 1b, 2). In addition, the magnitude of the PFS benefit 
from palbociclib-letrozole versus placebo-letrozole was 
consistent, regardless of baseline TFI or whether patients 
had received prior endocrine therapy (Figs. S2 and 1b).
Subpopulation treatment effect pattern plot 
analysis
To better understand whether the PFS treatment effect is 
influenced by baseline TFI, we performed a STEPP analy-
sis in patients who had received (neo)adjuvant endocrine 
therapy. The treatment effect of PFS was generally consist-
ent regardless of TFI (Fig. S3). No TFI cut-off changed the 
clinical benefit (Fig. S2).
Time to subsequent anticancer therapies
To explore whether the combination therapy had a potential 
impact on subsequent line therapies after permanent palboci-
clib discontinuation, analyses of time to initiation of first and 
second subsequent therapies were conducted. Median time 
from randomization to the initiation of the first subsequent 
therapy was 28.0 (95% CI 23.6–29.6) versus 17.7 (14.3–21.5) 
months with palbociclib–letrozole versus placebo-letrozole 
(Fig. 3a). The second subsequent systemic anticancer therapy 
was also significantly delayed in the palbociclib-letrozole arm 
compared with the placebo-letrozole arm at 38.8 (95% CI, 
34.4‒not estimable) months versus 28.8 (25.7‒33.5) months, 
respectively (Fig. 3b). In both analyses, the 10 month differ-
ence in PFS benefit from palbociclib observed in the primary 
PFS analysis was preserved, suggesting that the treatment 
benefit of the first subsequent therapy was not compromised 
by palbociclib. The median time to first-line subsequent 
chemotherapy was 40.4 (34.7‒47.3) months versus 29.9 
months (25.6‒35.1) for patients treated with palbociclib-
letrozole versus placebo-letrozole (Fig. 3c).
Types of first subsequent therapy
Among 227 palbociclib–letrozole patients and 150 pla-
cebo–letrozole patients who received subsequent systemic 
anticancer therapies after permanent study treatment dis-
continuation, endocrine therapy was the most common first 
subsequent treatment in patients from both arms (60.8% and 
58.0%, respectively), followed by chemotherapy (36.6% and 
722 Breast Cancer Research and Treatment (2019) 174:719–729
1 3
a
b
723Breast Cancer Research and Treatment (2019) 174:719–729 
1 3
34.0%; Table S4). Some patients received a second subsequent 
therapy; common second therapies are listed in Table S5.
Safety
With the additional 15 months of follow-up, no new safety 
signals were observed for palbociclib-letrozole. Over the 
entire study period, permanent discontinuation because of 
all-causality treatment-emergent AEs occurred in 54 (12.2%) 
patients in the palbociclib arm and 13 (5.9%) in the placebo 
arm. Neutropenia was the most frequently reported any-grade 
AE with palbociclib-letrozole (81.8% vs 6.3% with placebo-
letrozole) (Table S6). Most events in the palbociclib-letrozole 
arm were of grade 3 severity (57.4%); however, neutropenia 
rarely led to permanent study discontinuation (n = 8 [1.8%]), 
and febrile neutropenia was rare (n = 9 [2.0%]). Treatment-
emergent serious AEs (SAEs) of any cause occurred in 
23.6% of palbociclib-letrozole patients and 15.3% of placebo- 
letrozole patients. Infections were the most commonly reported 
SAE in both arms (5.2% and 4.1%, respectively).
Patient‑reported outcomes
Patient-reported HRQOL as assessed by the FACT-B total 
score was maintained with palbociclib–letrozole. The over-
all change from baseline in FACT-B total scores was not 
significantly different (P = 0.629) between the palbociclib-
letrozole and placebo-letrozole arms. No statistically sig-
nificant differences were observed between the treatment 
arms in change from baseline scores for any of the subscales 
assessed (Fig. 4a). The results for patient-reported HRQOL 
were consistent across all subgroups, including patients with 
bone-only disease and long TFI (Fig. 4b).
Discussion
Single-agent sequential endocrine therapy, which is associ-
ated with less drug toxicity than chemotherapy, has been the 
recommended standard of care for HR+/HER2− ABC in the 
first-line setting [1–3]; however, resistance to single-agent 
endocrine therapy and relapse over time are inevitable. As 
such, further research is warranted on the inclusion of tar-
geted agents in endocrine-based therapy to delay resistance 
and prolong the window of endocrine sensitivity. Following 
the positive results from the PALOMA-1, -2, and -3 stud-
ies [4, 10, 11], MONALEESA-2, -3, and -7 [12, 13], and 
the MONARCH 2 and 3 studies [14, 15], the international 
treatment guidelines now include recommendations for the 
use of CDK4/6 inhibitors in combination with endocrine 
therapy for the treatment of pre-menopausal and post-meno-
pausal women with HR+/HER2‒ ABC as first-line standard 
therapy [1–3].
To date, PALOMA-2 offers the longest follow-up of any 
phase 3 study evaluating a CDK4/6 inhibitor in patients with 
ABC and no prior systemic treatment for their advanced dis-
ease. After 37.6 months of follow-up, palbociclib-letrozole 
consistently improved median PFS compared with placebo-
letrozole in the overall population and across all subgroups 
of patients with ER+/HER2‒ ABC. Of note, patients with 
a low disease burden or a demonstrated sensitivity to endo-
crine monotherapy derived substantial PFS benefit from 
the addition of palbociclib to letrozole (> 3 years median 
PFS); these findings were confirmed by a STEPP analysis of 
TFI. The PFS benefit for patients with a low disease burden 
receiving palbociclib-letrozole should also be viewed in the 
context of results from another analysis of the PALOMA-2 
population which concluded that patients without progres-
sion versus those who progressed showed a significantly 
greater delay in deterioration of HRQOL [16].
The role of abemaciclib plus letrozole or anastrozole as 
initial treatment for HR+/HER2‒ ABC is being investigated 
in the MONARCH 3 trial [15]. In contrast to the PALOMA-2 
study in which all subgroups of patients benefited from the 
addition of palbociclib to letrozole, an exploratory subgroup 
analysis from MONARCH 3 suggested that patients with a 
better prognosis at baseline (i.e., > 36 months TFI or bone-
only disease) derived no further benefit from the addition of 
abemaciclib to endocrine therapy. However, comparisons 
across studies can be confounding when the duration of 
follow-up is too short for accrual of events in patients with 
endocrine-sensitive disease or bone-only disease.
The updated PALOMA-2 results for the subgroup of 
patients with non-visceral disease who had not received pre-
vious endocrine therapy can also be viewed alongside the 
Fulvestrant and Anastrozole Compared in Hormonal Ther-
apy Naive Advanced Breast Cancer (FALCON) trial results 
[17]. In a pre-specified subgroup of 208 women who had not 
received prior endocrine therapy and who did not have vis-
ceral disease, the median PFS was 22.3 versus 13.8 months 
with fulvestrant versus anastrozole, respectively, HR 0.59 
(95% CI 0.42–0.84) [17]. Although cross-study com-
parisons are inexact, in PALOMA-2, the median PFS was 
Fig. 1  a Investigator-assessed progression-free survival (ITT popu-
lation). b Forest plot of investigator-assessed PFS overall and across 
subgroups (ITT population). BICR blinded independent central 
review, ECOG PS Eastern Cooperative Oncology Group perfor-
mance status, ET endocrine therapy, HR hazard ratio, IA investiga-
tor assessed, ITT intent-to-treat, LET letrozole, PFS progression-free 
survival, NE not estimable, NR not reached, PAL palbociclib, PBO 
placebo, TFI treatment-free interval. a: 1-sided P value from the log-
rank test. b: Per tumor site. c: Protocol-defined disease-free interval is 
equivalent to TFI in this analysis and refers to TFI since completion 
of prior (neo)adjuvant therapy and onset of metastatic disease or dis-
ease recurrence. d: A few patients initially enrolled as having measur-
able disease were later found to have non-measurable disease beyond 
bone-only disease
◂
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36.2 months (Fig. S3c) for women with non-visceral disease 
and no prior endocrine therapy who received palbociclib 
and letrozole, as compared to the 22.3 months PFS seen 
with fulvestrant in patients with non-visceral disease in the 
FALCON study. Among the patients who had not received 
prior endocrine therapy or had non-visceral disease in the 
a
b
c
Fig. 2  Investigator-assessed PFS in subgroups of patients (ITT pop-
ulation). Kaplan–Meier curves for a bone-only and b single disease 
site—both representing low disease burden—and c no prior endo-
crine therapy with non-visceral disease. HR hazard ratio, ITT intent-
to-treat, NE not estimable, PFS progression-free survival
725Breast Cancer Research and Treatment (2019) 174:719–729 
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Fig. 3  Kaplan–Meier estimates of time to initiation of subsequent 
systemic anticancer therapies (anticancer treatment included any 
anticancer related systemic therapy and surgery for the disease under 
study) (ITT population) a Time from randomization to first subse-
quent therapy. b Time from randomization to second subsequent ther-
apy (if the difference in time to initiation of the second subsequent 
therapy between the 2 treatment arms was shortened compared with 
the difference between the median PFS values, it may suggest that the 
treatment benefit of the first subsequent therapy was compromised. If 
the difference was similar, it suggests no compromise regarding the 
efficacy of the first subsequent therapy). c Time from randomization 
to first subsequent chemotherapy. EFS event-free survival, ITT intent-
to-treat
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PALOMA-2 study, those who received palbociclib-letrozole 
for > 3 years maintained a quality of life not significantly 
different from patients receiving placebo-letrozole therapy 
(Fig. 4); furthermore, this quality of life is similar to that of 
a normal healthy population.
The results for median time to initiation of the first and 
second subsequent systemic therapy in this study suggest 
that the treatment benefit of the first subsequent therapy was 
not compromised by palbociclib. Additional clinical studies 
are needed to confirm these findings.
Similarly, palbociclib plus letrozole therapy delayed the 
initiation of first subsequent chemotherapy. More than one-
third of patients in this study received chemotherapy as their 
first subsequent line of therapy after disease progression on 
the study drug, which could suggest theirs was a higher-risk 
disease. The longer the initiation of salvage chemotherapy 
can be postponed, the longer patients can be spared from 
increased toxicities associated with these drugs, which may 
have a more negative effect on quality of life than less toxic 
agents [18] and, more importantly, have limited efficacy after 
a
b
Fig. 4  Between-treatment comparison of changes from baseline for 
FACT-B scores (PRO analysis set included patients in the PRO-eval-
uable population [i.e., patients with a baseline and ≥ 1 postbaseline 
assessment before the end of the study treatment]) a FACT-B scales 
of overall scores. b FACT-B total score by subgroups. BC breast can-
cer, ECOG PS Eastern Cooperative Oncology Group performance 
status, FACT-B Functional Assessment of Cancer Therapy-Breast, 
FACT-G Functional Assessment of Cancer Therapy-General, LET 
letrozole, PAL palbociclib, PBO placebo, PRO patient-reported out-
come, TFI treatment-free interval, TOI Trial Outcome Index
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endocrine therapy failure. Thus, the observed prolonged 
time to initiation of first subsequent chemotherapy follow-
ing palbociclib is of clinical relevance to patients with ER+/
HER2− ABC because it postponed the onset of endocrine 
resistance and may offer a therapeutic advantage in a setting 
with unmet medical needs [18].
Of the patients who progressed on palbociclib–letrozole 
in the first-line setting, 70 (30.8%) and 49 (21.6%) in the 
next immediate line of therapy switched to fulvestrant and 
exemestane therapy, respectively. These data suggest that 
challenging patients with single-agent endocrine therapy is 
feasible following progression on CDK inhibitor therapy.
None of the phase 3 studies of CDK4/6 inhibitors as 
first-line treatment have reported overall survival. Due to 
the chronic and prolonged indolent nature of HR+ MBC, 
PALOMA-2 has not yet reached the prerequisite number 
of events to trigger overall survival analysis. In the absence 
of overall survival data, the median PFS durations for sub-
groups of patients in the first and immediate subsequent 
line of therapy post-progression are of interest. Our analy-
sis showed that the time to subsequent line was prolonged 
by the addition of palbociclib over endocrine therapy alone 
and treatment effect was maintained, which provides early 
evidence for the long-term impact on patient outcomes.
Conclusions
In this study, after approximately 15 additional months of 
follow-up, palbociclib-letrozole consistently improved PFS 
across all clinically relevant subgroups and substantially 
delayed the next line of therapy without decreasing its dura-
tion of use. Furthermore, the safety profile of the combi-
nation remained consistent with previous observations [4]. 
The PROs confirm that quality of life was maintained in the 
overall population and across subgroups. Collectively, these 
data reinforce that palbociclib-letrozole should be regarded 
as an important first-line therapy option for patients with 
HR+/HER2− ABC.
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